

**IPOs**

The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month.

Company Name	Last Financing Date	HQ Location	Description	Last Financing Size (Millions)	Lead Manager
InflaRx (IFRX)	13-Oct-17	Jena, Germany	Developer of therapeutics in the field of acute and chronic inflammation designed to prevent organ dysfunction or limit progression into organ failure.	100.01	J.P Morgan, Leerink Partners, BMO Capital Markets
OptiNose (OPTN)	13-Oct-17	Yardley, PA	Developer of exhalation delivery systems capable of high and deep intranasal deposition of medication.	120.00	BMO Capital Market, Jefferies, Piper Jaffray & Co., RBC Capital Markets

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
KSQ Therapeutics	2-Oct-17	Cambridge, MA	Early Stage VC	Developer of an industrialized functional genomics engine that utilizes a suite of proprietary CRISPR/Cas9 tools to identify novel pathways and targets involved in oncology and immuno-oncology.	76.00	Flagship Pioneering, Polaris Partners, ARCH Venture Partners, Alexandria Equities
Locus Biosciences	2-Oct-17	Research Triangle Park, NC	Early Stage VC	Developer of sequence-specific precision antimicrobials for human infectious diseases.	7.00	Tencent, North Carolina Biotech Center, Undisclosed Investors
Peptide Logic	2-Oct-17	San Diego, CA	Accelerator/ Incubator	Owner and operator of a biopharmaceutical company that combines the advantages of synthetic peptides and recombinant antibodies to create innovative semi-synthetic biologics for the treatment of chronic pain.	Undisclosed	JLABS
Recombinetics	2-Oct-17	Saint Paul, MN	Angel	Developer of gene editing technologies designed to manipulate deoxyribonucleic acid samples to add and activate genes to solve problems in biomedical research, livestock productivity, and animal-derived biomaterials for use in medical applications.	0.08	Undisclosed Investors
Cullinan Oncology	3-Oct-17	Boston, MA	Early Stage VC	Developer of externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work.	150.00	MPM Capital, F2 Ventures, Undisclosed Investors
Dominion Aesthetic Technologies	3-Oct-17	San Antonio, TX	Angel	Supplier of aesthetic medical devices designed to improve a patient's interface and mobility.	1.60	Florida Institute for the Commercialization of Public Research, Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Harbor MedTech	3-Oct-17	Irvine, CA	Early Stage VC	Operator of a medicine company that provides wound healing and tissue regeneration products.	5.37	Arsenal Capital Management, Undisclosed Investors
InfiCure Bio	3-Oct-17	Umeå, Sweden	PE Growth/Expansion	Developer of a pre-clinical mouse model that evaluates the effects of anti-fibrotic drugs.	Undisclosed	Partnerinvest Norr, Northen Light Capital, Vinnova
Invenra	3-Oct-17	Madison, WI	Later Stage VC	Developer of a platform to screen peptides and proteins to discover and develop new biologic drugs in areas like cancer, Alzheimer's disease, and diabetes.	2.93	Undisclosed Investors
Recursion Pharmaceuticals	3-Oct-17	Salt Lake City, UT	Early Stage VC	Provider of a drug discovery platform that uses biological tools to build cellular disease models, enabling biologists to query and understand the results of phenotypic screens, drug screens, and target discovery screens with immediate access to raw images and underlying data.	60.00	Data Collective, Lux Capital, Obvious Ventures, Advantage Capital, Felicis, Epic, AME Cloud Ventures, Mubadala, Menlo Ventures, Charles River Ventures, Two Sigma, Undisclosed Investors
The Biomed International	3-Oct-17	Kelowna, Canada	PIPE	Producer of medical marijuana and provider of scientific research and services related to the medical cannabis industry.	0.65	Alumina Partners
Imagin Medical (IME)	4-Oct-17	Vancouver, Canada	PIPE	Developer of a technology intended for the early detection of cancer through the use of endoscopes.	0.73	Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Immatics	4-Oct-17	Tübingen, Germany	Later Stage VC	Developer of immunotherapies designed to use the body's own immune system to fight cancer.	58.00	Amgen, Wellington Partners, dievini Hopp BioTech, AT Impf, Undisclosed Investors
Koutif Therapeutics	4-Oct-17	Cleveland, OH	Angel	Operator of a drug discovery company intended to fight inflammatory diseases.	0.60	Undisclosed Investors
OMEICOS Therapeutics	4-Oct-17	Berlin, Germany	Early Stage VC	Developer of a first-in-class small molecule therapy designed for the treatment and prevention of atrial fibrillation.	Undisclosed	Remiges Ventures, Vesalius Biocapital Partners and SMS Group; SICAR, High-Tech Gründerfonds, KfW Bankengruppe, IBB Beteiligungsgesellschaft, The Falck Revocable Trust, Ascenion, Undisclosed Investors
Palleon Pharmaceuticals	4-Oct-17	Waltham, MA	Early Stage VC	Developer of a biotechnology platform designed to offer a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.	47.60	SR One, Pfizer, Vertex Ventures HC, Takeda Ventures, AbbVie Ventures

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
3T Biosciences	5-Oct-17	Palo Alto, CA	Seed Round	Provider of medical research and development facilities that incorporate synthetic biology and machine learning to discover novel targets in order to cure cancer and other T-cell mediated diseases.	12.00	Thiel Capital, Asset Management Ventures, Sean Parker, Undisclosed Investors
Harmony Biosciences	5-Oct-17	Plymouth Meeting, PA	Early Stage VC	Developer of biopharmaceuticals designed to identify, develop, and commercialize novel treatment options for patients with rare central nervous system disorders.	270.00	Valor Equity Partners, Fidelity Management & Research, HBM Healthcare Investments, Vivo Capital, venBio, Novo, Nan Fung Capital, Paragon Biosciences, California Institute for Quantitative Biosciences
SCA Pharmaceuticals	5-Oct-17	Little Rock, AR	PE Growth/Expansion	Developer of unit dosed oral syringes, drug shortage medications, and compounded pharmaceutical products for hospitals, pharmacies, and ambulatory surgery centers.	Undisclosed	Enhanced Equity Funds
Calcivis	6-Oct-17	Edinburgh, United Kingdom	Later Stage VC	Developer of a dental imaging system designed to transform the assessment and management of demineralization associated with dental caries and erosion.	1.63	Archangels Informal Investment, Scottish Enterprise, Julz, Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
PanOptica	6-Oct-17	Bernardsville, NJ	Early Stage VC	Provider of therapies for debilitating vision loss, age-related muscular degeneration, and diabetic retinopathy.	11.00	SV Life Sciences Advisers, Third Rock Ventures
Qidni Labs	6-Oct-17	Kitchener, Canada	Accelerator/ Incubator	Developer of renal replacement therapy devices for patients with end-stage renal disease.	0.55	43North
Sequella	6-Oct-17	Rockville, MD	Later Stage VC	Developer of antibiotics for the treatment of tuberculosis and gastritis infections.	0.63	Undisclosed Investors
Blaze Bioscience	9-Oct-17	Seattle, WA	Later Stage VC	Developer of a cancer surgery technology providing real-time, high resolution visualization of cancer cells for surgeons to achieve better resection of tumors while simultaneously preserving healthy tissues.	16.11	Undisclosed Investors
MT-Medikals	9-Oct-17	Moscow, Russia	Early Stage VC	Operator of a biotechnology firm intended to provide treatment of multidrug-resistant tuberculosis.	0.19	Primer Capital, Undisclosed Investors
Sygnature Discovery	9-Oct-17	Nottingham, United Kingdom	PE Growth/ Expansion	Provider of integrated drug discovery and research services.	Undisclosed	Phoenix Equity Partners
Theraworx	9-Oct-17	Asheville, NC	Later Stage VC	Provider of specialty care packs for peri-care prior to foley catheter insertion and on-going foley maintenance.	41.57	Asgard Partners, Undisclosed Investors
Azura Ophthalmics	10-Oct-17	Tel Aviv, Israel	Early Stage VC	Developer of innovative therapies for the treatment of meibomian gland dysfunction.	16.00	TPG Biotech, Brandon Capital, OrbiMed, Ganot Capital
Crescita Therapeutics	10-Oct-17	Mississauga, Canada	Secondary Transaction - Private	Provider of a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions and diseases.	Undisclosed	Knight Therapeutics

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Engage Therapeutics	10-Oct-17	Summit, NJ	Early Stage VC	Developer of a new drug-device combination therapy for people who experience uncontrolled epileptic seizures.	23.60	TPG Biotech, Adage Capital Management, Lifescivc, Lumira Capital, Undisclosed Investors
InjectSense	10-Oct-17	Emeryville, CA	Angel	Developer of an injectable wireless pressure sensor designed to monitor patient IOP profiles for glaucoma by focusing on minimally invasive assistance to generate clinically actionable information for therapy management and outcome.	9.84	Undisclosed Investors
KalVista (KALV)	10-Oct-17	Porton Down, United Kingdom	PIPE	Developer of small-molecule pharmaceuticals designed for a variety of hereditary diseases.	9.10	Merck & Co
Ribon Therapeutics	10-Oct-17	Lexington, MA	Early Stage VC	Developer of novel therapeutics targeting monoADP-ribosylating PARPs for cancer.	43.50	US Venture Partners, Deerfield Management, Osage University Partners, The Column Group, Undisclosed Investors
Wellesley Pharmaceuticals	10-Oct-17	Newtown, PA	Later Stage VC	Developer of drugs for the treatment of nocturia.	3.78	Axella Bioventures, Undisclosed Investors
Asepticys	11-Oct-17	New Orleans, LA	Early Stage VC	Developer of medical disinfection products that kill and deactivate pathogenic organisms across all microbial kingdoms and are effective across a broad spectrum of microbial pathogens.	2.65	Undisclosed Investors
Biophytis (ALBPS)	11-Oct-17	Paris, France	PIPE	Developer of drugs for metabolic disorders and age-related diseases.	12.40	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
GrowHealthy	12-Oct-17	Lake Wales, FL	Corporate	Operator of a marijuana farm offering medical marijuana, clinics, and pharmaceutical-grade medical marijuana cannabis-infused products.	6.00	iAnthus Capital Management
Janpix	12-Oct-17	London, United Kingdom	Early Stage VC	Developer of therapies to treat hematological tumors and glioblastomas.	17.70	Medicxi Ventures, Undisclosed Investors
LabGenius	12-Oct-17	London, United Kingdom	Angel	Provider of a closed-loop platform intended to develop a new generation of biological products using artificial intelligence, automation, and synthetic DNA.	2.77	Undisclosed Investors
Realm Therapeutics (RLM)	12-Oct-17	Malvern, PA	PIPE	Developer of small molecule therapies for the treatment of inflammatory diseases with potential applications in dermatology, ophthalmology, and other diseases.	26.00	OrbiMed, BVF Partners, RA Capital Management, Abingworth BioEquities Master Fund, Polar Capital
Techulon	12-Oct-17	Blacksburg, VA	Angel	Operator of a biotechnology platform that facilitates delivery of nucleic acids for a variety of therapeutic applications, enabling researchers to develop a targeted approach to inhibit growth of common MDR bacteria and new strains of bacteria.	0.20	Undisclosed Investors
Thermedical	12-Oct-17	Waltham, MA	Later Stage VC	Developer of a thermal ablation therapy designed to treat cancer and cardiac arrhythmias.	8.75	Undisclosed Investors
VirionHealth	12-Oct-17	Coventry, United Kingdom	Early Stage VC	Developer of biological antivirals created to offer improved therapeutics for respiratory viral infections.	17.28	Abingworth
ENTvantage Dx	13-Oct-17	Austin, TX	Early Stage VC	Developer of an in-office diagnostic test kit designed to determine the cause of ear, nose, and throat illnesses.	3.30	Keiretsu Forum, Undisclosed Investors
FirstString Research	13-Oct-17	Mount Pleasant, SC	Later Stage VC	Provider of therapeutics designed to engage in the translation of cell-cell communication and cell-cell adhesion science into a pipeline of drugs for wound healing and complex tissue regeneration.	6.58	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape



**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Prima-Temp	13-Oct-17	Boulder, CO	Later Stage VC	Developer of a device designed to provide precise and accurate core body temperature measurements.	5.43	Undisclosed Investors
Quadron Capital (QCC)	13-Oct-17	Vancouver, Canada	PIPE	Provider of ancillary equipment, products, and services designed and structured to address the complex needs and requirements of authorized cannabis industry participants.	0.81	Undisclosed Investors
SlipChip	13-Oct-17	Chicago, IL	Early Stage VC	Developer of a disruptive microfluidic platform designed to offer quantitative and digital nucleic acid analysis.	28.94	Undisclosed Investors
LambdaVision	16-Oct-17	Farmington, CT	Early Stage VC	Developer of a protein-based, retinal implant technology that utilizes a light-activated protein to stimulate the retinas of patients with impaired vision or sight loss due to retinal degenerative diseases.	0.50	Connecticut Innovations
Aperiomics	17-Oct-17	Ashburn, VA	Seed Round	Developer and provider of a disease diagnosis technology that can simultaneously test for all pathogens.	0.51	Pipeline Angels, Chemical Angel Network
Cydan	17-Oct-17	Cambridge, MA	Early Stage VC	Operator of an orphan drug accelerator designed to accelerate therapies through clinical, regulatory, and commercial development for treating patients with more than 7,000 rare diseases with approximately 400 approved treatments.	34.00	New Enterprise Associates, Longitude Capital, Pfizer Venture Investments, Alexandria Venture Investments, Lundbeckfond Ventures
DiFusion Technologies	17-Oct-17	Austin, TX	Angel	Developer of metallic ion therapeutic agents technology designed for antimicrobial, cellular repair, tissue regeneration, bone growth, scaffold construction, and increased angiogenesis.	3.47	Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Forty Seven	17-Oct-17	Menlo Park, CA	Early Stage VC	Developer of next generation immuno-oncology therapies.	75.00	Wellington Management, Clarus Ventures, Lightspeed Venture Partners, Sutter Hill Ventures, GV
Gemini Therapeutics	17-Oct-17	Cambridge, MA	Early Stage VC	Developer of precision therapeutics created to treat genetically-defined dry age-related macular degeneration and associated rare genetic diseases.	42.50	Atlas Venture, Lightstone Ventures, OrbiMed
Lumicell	17-Oct-17	Wellesley, MA	Later Stage VC	Developer of an intraoperative imaging system that includes a margin-targeted injectable imaging agent and hand-held imaging device that gives surgeons real-time visual feedback of residual cancer in the tumor bed.	27.48	Kodiak Venture Partners, Launch Capital, BlueIO, Sigmas Emerging Markets, Undisclosed Investors
Mission Bio	17-Oct-17	San Francisco, CA	Early Stage VC	Developer of technologies to analyze single cells within complex biological systems designed to detect critical information not observable from bulk sample analysis.	10.00	Mayfield Fund, Keiretsu Forum, Keiretsu Capital
TAI Diagnostics	17-Oct-17	Milwaukee, WI	Early Stage VC	Developer of a non-invasive and highly sensitive diagnostic test designed to monitor the health of transplanted organs.	1.77	Undisclosed Investors
Critical Outcome Technologies (COT)	18-Oct-17	London, Canada	PIPE	Developer of targeted therapeutic products for ovarian and other gynecological cancers that help restore normal cell signaling in cancer with p53 mutations.	2.07	Undisclosed Investors
CureVac	18-Oct-17	Tübingen, Germany	Later Stage VC	Developer of mRNA-molecules for therapeutic and prophylactic vaccines designed to instruct the human body to produce its own proteins to fight a wide range of diseases.	53.64	Eli Lilly and Company

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Kairos BioMedical	18-Oct-17	Honolulu, HI	Angel	Owner and operator of an evidence-based biomedical company that discovers, develops, and commercializes immuno preventative and therapeutic products in partnership with leading companies and institutions.	0.18	Undisclosed Investors
Miromatrix	18-Oct-17	Eden Prairie, MN	Later Stage VC	Developer of a perfusion decellularization technology designed to manufacture human organs for transplantation.	1.71	Undisclosed Investors
Prenetics	18-Oct-17	Quarry Bay, Hong Kong	Later Stage VC	Developer of a pharmacogenomics platform designed to offer personalized, predictive, and preventive treatments.	40.00	Beyond Ventures and Alibaba Entrepreneurs Fund; Yuantai Investment Partners, MFUND, eGarden Ventures
Seventh Sense Biosystems	18-Oct-17	Medford, MA	Later Stage VC	Developer of a blood collection device designed to make blood testing more convenient and virtually painless.	12.50	Novartis, LabCorp and Polaris Partners, Ionis Pharmaceuticals, Flagship Ventures
Ambry Genetics	19-Oct-17	Aliso Viejo, CA	PE Growth/Expansion	Operator of a genetics diagnostics company designed to provide a comprehensive suite of genetic testing applications for inherited and non-inherited diseases.	400.00	Innovation Network Corporation of Japan
Claret Medical	19-Oct-17	Santa Rosa, CA	Later Stage VC	Developer of a cerebral protection system designed to reduce the risk of stroke during transcatheter aortic valve replacement.	21.21	Lightstone Ventures, Easton Capital Investment Group, HealthCor Partners Management, Incept, Santé Ventures

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
Helix BioPharma (HBP)	19-Oct-17	Richmond Hill, Canada	PIPE	Developer of an oncology platform technology designed to induce an increase in pH locally at the site of cancerous cells in the body to create an environment inhospitable to their continued growth and survival.	4.91	Undisclosed Investors
Microbix Biosystems (MBX)	19-Oct-17	Mississauga, Canada	PIPE	Manufacturer and distributor of infectious disease antigens and biological products for the global diagnostics industry, notably antigens used in immunoassays or quality assurance and proficiency testing controls.	1.89	Undisclosed Investors
Replicel Life Sciences (RP)	19-Oct-17	Vancouver, Canada	PIPE	Developer of drugs intended for autologous cell therapies.	1.15	Undisclosed Investors
Synthego	19-Oct-17	Redwood City, CA	Early Stage VC	Developer of a precision tool to automate genome engineering research.	Undisclosed	Intel Capital
Veritas Pharma (VRT)	19-Oct-17	Vancouver, Canada	PIPE	Developer of innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis, and epilepsy.	2.61	Marapharm Ventures, Undisclosed Investors
Hubei 377 Biotechnology Company	20-Oct-17	Beijing, China	Secondary Transaction - Private	Manufacturer of biotechnological devices, including DNA and RNA synthesis instruments, gene analyzers, synthesizers, amplifiers, protein purifiers, automated workstations, and other related products.	15.90	Anhui Anke Biotechnology
Prelude Therapeutics	20-Oct-17	Newark, DE	Angel	Developer of medicines targeting chromatin function for the treatment of cancers and rare diseases.	12.00	Undisclosed Investors
RenovaCare (RCAR)	20-Oct-17	New York, NY	PIPE	Developer of autologous stem cell therapies, including treatments that target the skin, intended for regeneration of human organs.	2.30	Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
ADC Therapeutics	23-Oct-17	Epalinges, Switzerland	Early Stage VC	Developer of antibody and non-antibody drug conjugate products that target hematological cancers and tumor cells.	200.00	Auven Therapeutics, Wild Family Office, AstraZeneca, Redmile Group, Undisclosed Investors
Appili Therapeutics	23-Oct-17	Halifax, Canada	Early Stage VC	Developer of oral antibiotics for the treatment of infectious diseases.	3.06	Innovacorp, Undisclosed Investors
GeneCapture	23-Oct-17	Huntsville, AL	Angel	Developer of medical diagnostic devices designed to detect and identify pathogens.	0.17	Undisclosed Investors
MYM Nutraceuticals (MYM)	23-Oct-17	Vancouver, Canada	PIPE	Provider of bio-pharmaceutical research services intended to produce quality cannabis growing facilities and developer of high-end organic medicinal marijuana supplements and topical products.	3.46	Undisclosed Investors
Purigen Biosystems	23-Oct-17	Pleasanton, CA	Early Stage VC	Developer of an anisotachophoresis chip for nucleic acid preparation to be used for genomic analyses.	20.85	Roche Venture Fund, Startx, 5AM Ventures, Western Investments Capital, Undisclosed Investors
Helixbind	24-Oct-17	Marlborough, MA	Angel	Developer of a pathogen identification platform that offers rapid detection and unequivocal identification of bloodstream infections direct from a whole blood specimen and without the need for blood culture.	286.00	Undisclosed Investors

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
ImmuneTarget	24-Oct-17	San Diego, CA	Angel	Developer of a research platform for targeted therapies created to treat cancers and autoimmune diseases.	0.86	Undisclosed Investors
Proteon Pharmaceuticals	24-Oct-17	Lodz, Poland	Early Stage VC	Developer of bacteriophage-based products used as an alternative to antibiotics in combating pathogenic bacteria, including antibiotic resistant microbes.	Undisclosed	Aqua-Spark
Sirona Biochem (SBM)	24-Oct-17	Vancouver, Canada	PIPE	Developer of a proprietary platform technology with a specialization in the stabilization of carbohydrate molecules for the cosmetic and drug discovery industries.	0.64	Undisclosed Investors
YmAbs	24-Oct-17	New York, NY	Early Stage VC	Developer of immunotherapy cancer treatments created to drive multiple product candidates in select solid tumor cancers.	50.00	HBM Healthcare Investments, Undisclosed Investors
Gemneo Bioscience	25-Oct-17	Scottsdale, AZ	Angel	Developer of an immune cell profiling technology designed to provide more optimal cancer treatments and help physicians better understand and tailor treatments around individual patient's disease and immune responses.	0.10	Undisclosed Investors
Waverley Pharma (WAVE)	25-Oct-17	Winnipeg, Canada	PIPE	Developer of small molecule therapeutics for the treatment of cancer.	4.47	Undisclosed Investors
Celsee Diagnostics	26-Oct-17	Plymouth, MI	Later Stage VC	Developer of a fully-automated circulating tumor cell detection system that has the ability to analyze biomarkers at a single-cell level at the site of collection.	7.91	Undisclosed Investors
Whistler Medical Marijuana	26-Oct-17	Whistler, Canada	Angel	Producer of organic medical marijuana.	0.40	Undisclosed Investors

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape

**Private Equity Placements and Venture Capital Rounds**

The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Company Name	Last Financing Date	HQ Location	Round	Description	Last Financing Size (Millions)	Investor(s)
BioTuring	27-Oct-17	San Diego, CA	Angel	Developer of a cloud-based software platform utilizing machine learning and bioinformatics algorithms to store and analyze genomic data.	1.02	Undisclosed Investors
Kymera	30-Oct-17	Cambridge, MA	Early Stage VC	Operator of a biotech firm enaging in the field of targeted protein degradation to access the body's innate protein recycling machinery.	30.00	Atlas Venture, Lilly Ventures, Amgen Ventures
Maxwell MRI	30-Oct-17	Brisbane, Australia	Early Stage VC	Provider of a prostate cancer detection and diagnosis platform that combines deep learning with modern medical imaging and integrates with existing PACS systems.	Undisclosed	Main Sequence Ventures
Personal Genome Diagnostics	30-Oct-17	Baltimore, MD	Later Stage VC	Developer of cancer genome testing products designed to help in identifying tumor mutations with accuracy by identifying alterations in complex cancer genomes.	65.37	Undisclosed Investors
Ribometrix	31-Oct-17	Greenville, NC	Seed Round	Developer of RNA-targeted small molecule drugs created for the treatment of rare, orphan, and unmet human diseases.	7.50	SV Health Investors, Hatteras Venture Partners, AbbVie Ventures, MP Healthcare Venture Management, Alexandria Venture Investments

**Mergers and Acquisitions**

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Stallergenes Greer	Medic Savoure	Dutton, Canada	2-Oct-17	Provider of allergy immunotherapy products, including diagnostics and AIT treatment products.	Undisclosed
Abbott Laboratories	Alere	Waltham, MA	3-Oct-17	Manufacturer of consumer and professional medical diagnostic products designed for the detection of diseases.	4600.00
Undisclosed	Apicore US	Somerset, NJ	3-Oct-17	Developer and manufacturer of specialty active pharmaceutical ingredients and pharmaceuticals.	105.00
Gilead Sciences	Kite Pharma	Santa Monica, CA	3-Oct-17	Developer of active cancer immunotherapies that express either a chimeric antigen receptor or a T-cell receptor, addressing both hematological and solid tumor cancers.	12000.00
Fagron	All Chemistry	Sao Paulo, Brazil	5-Oct-17	Distributor of pharmaceutical raw materials and provider of testing and microbiological analysis.	Undisclosed
Medtronic	Animas (Insulin pump business)	Wayne, PA	5-Oct-17	Manufacturer and developer of medicines and vaccines for the treatment of diabetes.	Undisclosed
Prescient Medicine	PGxl Laboratories	Louisville, KY	5-Oct-17	Provider of pharmacogenetics services engaged with the development of personalized medicine at the level of discovery, assay development, and clinical testing.	Undisclosed
Emergent BioSolutions	ACAM2000	Paris, France	6-Oct-17	Developer of a vaccine for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection.	125.00
First Coin Capital	Bradmer Pharmaceuticals (BMR.H)	Toronto, Canada	10-Oct-17	Provider of new and innovative cancer therapies.	Undisclosed
Kerry Group	Ganeden Biotech	Mayfield Heights, OH	11-Oct-17	Developer of patented probiotic ingredients designed for making over-the-counter probiotic products.	Undisclosed
Lupin	Sybiomix Therapeutics	Newark, NJ	11-Oct-17	Developer of a potent, next-generation, 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties that makes efficacious and well-tolerated delivery in a single dose, enabling patients to get treated from bacterial vaginosis.	150.00
Erkafarm	Rosta Group (Certain Subsidiaries)	Saint Petersburg, Russia	12-Oct-17	Wholesaler and retailer of pharmaceutical products.	Undisclosed
Priority Aviation	Telluride Health	Telluride, CO	12-Oct-17	Operator of a medical cannabis enterprise.	Undisclosed

Source: Pitchbook

Compiled by: Lea Keller and Morgan Reape



**Mergers and Acquisitions**

The following table includes mergers and acquisitions for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month.

Acquirer	Target	HQ Location	Date	Description	Transaction Value (Millions)
Karo Pharma	Weifa	Oslo, Norway	12-Oct-17	Provider of pharmaceutical drugs for menstrual pain, headaches, swelling and pain in muscles and joints, wound treatment, and other areas.	163.61
Bracco Imaging	SurgVision	Harde, Netherlands	18-Oct-17	Provider of a molecular surgical imaging technology designed to discriminate between healthy and cancerous tissue.	Undisclosed
Fortive	Landauer (LDR)	Glenwood, IL	19-Oct-17	Provider of integrated radiation safety products and services intended to improve public health and safety by advancing research, technology, and services related to radiation measurement and medical physics.	770.00
Catalent	Catalent Bloomington	Bloomington, IN	23-Oct-17	Provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products	950.00
Finch Therapeutics	Crestovo	Cambridge, MA	23-Oct-17	Developer of an orally-administered microbiome designed to deliver novel therapeutics that involves transfer of good bacteria from one person's gut to another.	Undisclosed
Clinigen Group	International Medical Management Company	Minato, Japan	23-Oct-17	Supplier of unlicensed medicines, pharmaceuticals, medical equipment, and cosmetics.	Undisclosed
Grey Cloak Tech	Eqova Life Sciences	Denver, CO	24-Oct-17	Developer of clinical grade full spectrum hemp oil products developed in compliance with cGMP, formulated by medical experts with natural ingredients combined together, and are sold under the CannaBio brand via partnerships with licensed medical practitioners to use with their patients.	Undisclosed
Merck & Co	Rigontec	Munich, Germany	26-Oct-17	Developer of RNA-based immuno-therapeutics for cancer and viral diseases.	553.06
Maricann Group	NanoLeaf Technologies	Toronto, Canada	27-Oct-17	Operator of a biotechnology company that processes licensing rights to a number of globally patented technologies that provide proven pharmaceutical, nutraceutical, cosmetic, and functional beverage drug delivery formulations.	31.31